Table 1.
Distribution of clinical variables among HCC patients (n = 41).
| No. of patients (%) | |
|---|---|
| Sex | |
| Female | 6 (14.6%) |
| Male | 35 (85.4%) |
| Age | |
| < 50 | 7 (17.1%) |
| > 50 | 34 (82.9%) |
| HBsAg | |
| No | 11 (26.8%) |
| Yes | 30 (73.2%) |
| Anti‐HCV | |
| No | 38 (92.7%) |
| Yes | 3 (7.3%) |
| ALT (U·L−1) | |
| < 45 | 37 (90.2%) |
| > 45 | 4 (9.8%) |
| AFP (U·L−1) | |
| < 20 | 26 (63.4%) |
| > 20 | 15 (36.6%) |
| GGT (U·L−1) | |
| < 45 | 19 (46.3%) |
| > 45 | 22 (53.7%) |
| Liver cirrhosis | |
| No | 12 (29.3%) |
| Yes | 29 (70.7%) |
| Tumor number | |
| Single | 32 (78.0%) |
| Multiple | 9 (22.0%) |
| Tumor size (cm) | |
| < 5 | 18 (43.9%) |
| > 5 | 23 (56.1%) |
| Tumor capsule | |
| No | 24 (58.5%) |
| Partial | 10 (24.4%) |
| Complete | 7 (17.1%) |
| MVI | |
| No | 19 (46.3%) |
| Yes | 22 (53.7%) |
| Tumor differentiation | |
| I–II | 20 (48.8%) |
| II–III | 21 (51.2%) |
| Adjuvant treatment | |
| No | 13 (31.7%) |
| Yes | 28 (68.3%) |
| BCLC | |
| 0‐A | 31 (75.6%) |
| B | 10 (24.4%) |
| CNLC | |
| Ia‐Ib | 33 (80.5%) |
| IIa‐IIb | 8 (19.5%) |
ALT, alanine aminotransferase; GGT, γ‐glutamyl transpeptidase; HBV, hepatitis B virus; HCV, hepatitis C virus.